metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus Standard of Care (SoC)
	nivolumab plus ipilimumab plus SoC
	CheckMate 9LA, 2021 Lancet Oncol 2021 Jan 18;S1470-2045(20)30641-0. ESMO Open. 2021 Oct 1 NCT03215706	RCT	mNSCLC - L1 - all population	nivo plus ipi and chemo (2 cycle)	chemotherapy platine combination	patient treated as First Line Therapy in squamous or non-squamous stage IV or recurrentNSCLC	361 / 358	some concern	conclusif	demonstrated 31 % decrease in deaths (OS) (PE) demonstrated 30 % decrease in progression or deaths (PFS) (PE) suggested 34 % decrease in deaths (OS) (extension) suggested 32 % decrease in PFS (extension) more...

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

RCT

mNSCLC - L1 - all population

nivo plus ipi and chemo (2 cycle)

chemotherapy platine combination

patient treated as First Line Therapy in squamous or non-squamous stage IV or recurrentNSCLC

361 / 358